MetaVia Inc. (NASDAQ:MTVA) Short Interest Up 82.9% in February

MetaVia Inc. (NASDAQ:MTVA) was the recipient of a large increase in short interest in February. As of February 27th, there was short interest totaling 102,676 shares, an increase of 82.9% from the February 12th total of 56,146 shares. Currently, 4.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 131,429 shares, the days-to-cover ratio is currently 0.8 days. Based on an average daily trading volume, of 131,429 shares, the days-to-cover ratio is currently 0.8 days. Currently, 4.7% of the shares of the stock are sold short.

MetaVia Price Performance

Shares of MTVA stock remained flat at $1.61 during trading hours on Friday. 34,515 shares of the company’s stock traded hands, compared to its average volume of 242,730. The stock has a market capitalization of $3.54 million, a P/E ratio of -0.19 and a beta of 0.33. MetaVia has a 52-week low of $1.34 and a 52-week high of $23.10. The stock has a 50-day simple moving average of $2.92 and a 200 day simple moving average of $7.21.

Analyst Ratings Changes

A number of research firms have recently issued reports on MTVA. Wall Street Zen downgraded shares of MetaVia from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Weiss Ratings restated a “sell (d-)” rating on shares of MetaVia in a research report on Monday, December 22nd. Finally, HC Wainwright lifted their price target on MetaVia from $12.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, MetaVia presently has an average rating of “Hold” and an average target price of $36.50.

Hedge Funds Weigh In On MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC purchased a new stake in shares of MetaVia Inc. (NASDAQ:MTVA) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.14% of MetaVia as of its most recent SEC filing. 1.37% of the stock is owned by hedge funds and other institutional investors.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.